In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Online physician community may help with postmarket surveillance

This article was originally published in The Silver Sheet

Executive Summary

CDRH has signed an "evaluation agreement" with an online forum for physicians to determine whether it can help the center with its postmarket surveillance challenges. Cambridge, Mass.-based Sermo - which bills itself as the nation's largest online physician community - will work with FDA "to explore opportunities and introduce new ways in which physicians can become efficiently involved in the surveillance of medical product safety," says company VP Alex Frost. The site allows doctors to discuss various topics with each other and also lets them formulate quantitative survey questions. For example, during a discussion about a certain type of adverse event, a participant could send out a survey question asking others whether they have seen similar issues. The system would then tabulate the results. Precisely how Sermo could be incorporated into the postmarket surveillance infrastructure of CDRH, or possibly FDA as a whole, remains to be seen





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts